Right heart failure in pregnant women with cyanotic congenital heart disease — The good, the bad and the ugly

Zengin, Elvin; Sinning, Christoph; Schrage, Benedikt; Mueller, Götz; Klose, Hans; Sachweh, JS; Goepfert, Matthias S.; Hueneke, B.; Blankenberg, Stefan; Kozlik‐Feldmann, Rainer

doi:10.1016/j.ijcard.2015.10.036

Cited by 3 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bed rest and fluid balance with diuretics and inotropes could be used. In cases of pulmonary arterial hypertension, targeted therapy with phosphodiesterase‐5 inhibitors or prostaglandins may be considered 23–26 …”

Section: Managing Pregnancies In Patients With Chronic Heart Failurementioning

confidence: 99%

“…In cases of pulmonary arterial hypertension, targeted therapy with phosphodiesterase-5 inhibitors or prostaglandins may be considered. [23][24][25][26] Iron deficiency is common in heart failure, is often overlooked and has an independent adverse effect on cardiac function and for maternal health. [27][28][29] Also in pregnant women, iron deficiency (both with and without anaemia) is highly prevalent.…”

Section: Managing Pregnancies In Patients With Chronic Heart Failurementioning

confidence: 99%

See 1 more Smart Citation

Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy

Sliwa

Meer

Petrie

et al. 2021

European J of Heart Fail

View full text Add to dashboard Cite

This position paper focusses on the pathophysiology, diagnosis and management of women diagnosed with a cardiomyopathy, or at risk of heart failure (HF), who are planning to conceive or present with (de novo or previously unknown) HF during or after pregnancy. This includes the heterogeneous group of heart muscle diseases such as hypertrophic, dilated, arrhythmogenic right ventricular and non‐classified cardiomyopathies, left ventricular non‐compaction, peripartum cardiomyopathy, Takotsubo syndrome, adult congenital heart disease with HF, and patients with right HF. Also, patients with a history of chemo‐/radiotherapy for cancer or haematological malignancies need specific pre‐, during and post‐pregnancy assessment and counselling. We summarize the current knowledge about pathophysiological mechanisms, including gene mutations, clinical presentation, diagnosis, and medical and device management, as well as risk stratification. Women with a known diagnosis of a cardiomyopathy will often require continuation of drug therapy, which has the potential to exert negative effects on the foetus. This position paper assists in balancing benefits and detrimental effects.

show abstract

Section: Managing Pregnancies In Patients With Chronic Heart Failurementioning

confidence: 99%

Section: Managing Pregnancies In Patients With Chronic Heart Failurementioning

confidence: 99%

Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy

Sliwa

Meer

Petrie

et al. 2021

European J of Heart Fail

View full text Add to dashboard Cite

show abstract

“…Pregnant patients with PAH should be closely monitored at a centre with expertise in PAH, as well as physicians with experience in managing high-risk pregnancies and in critical care using extracorporeal procedures. Patients, especially those with Eisenmenger's syndrome, are particularly at risk not only during pregnancy and delivery, but particularly also in the immediate post-partum period [19].…”

Section: General Measures For Paɵents With Pulmonary Hypertensionmentioning

confidence: 99%

General measures and supportive therapy for pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018

Grünig

Benjamin

Krüger

et al. 2018

International Journal of Cardiology

View full text Add to dashboard Cite

In the summer of 2016, delegates from the German Respiratory Society, the German Society of Cardiology and the German Society of Pediatric Cardiology met in Cologne, Germany, to define consensus-based practice recommendations for the management of patients with pulmonary arterial hypertension (PAH). These recommendations were built on the 2015 European Pulmonary Hypertension guidelines aiming at their practical implementation, considering country-specific issues, and including new evidence, where available. To this end, a number of working groups was initiated, one of which was specifically dedicated to general measures (i.e. physical activity/supervised rehabilitation, pregnancy/contraception, elective surgery, infection prevention, psychological support, travel) and supportive therapy (i.e. anticoagulants, diuretics, oxygen, cardiovascular medications, anaemia/iron deficiency, arrhythmias) for PAH. While the European guidelines provide detailed recommendations for the use of targeted PAH therapies as well as supportive care, detailed treatment decisions in routine clinical care may be challenging, and the relevance of supportive care is often not sufficiently considered. In addition, new evidence became available, thus requiring a thorough reevaluation of specific recommendations. The detailed results and recommendations of the working group on general measures and supportive therapy for PAH, which were last updated in the spring of 2018, are summarized in this article.

show abstract

Cardiac Conditions That May Affect Pregnancy

Wilson¹

2023

Maternal Cardiac Care

View full text Add to dashboard Cite

Right heart failure in pregnant women with cyanotic congenital heart disease — The good, the bad and the ugly

Cited by 3 publications

References 6 publications

Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy

Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy

General measures and supportive therapy for pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018

Cardiac Conditions That May Affect Pregnancy

Contact Info

Product

Resources

About